Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Matthias, Calamia"'
Publikováno v:
Journal of Medical Economics. 24:14-24
Publikováno v:
JAMA Network Open. 6:e234226
Publikováno v:
Journal of medical economics. 24(sup1)
Polatuzumab vedotin-bendamustin-rituximab (PBR) and tafasitamab-lenalidomide (Tafa-L) were approved recently for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in autologous stem cell transplant (ASCT) ineligible patients. We performed
Autor:
Briana M. Choi, Rachel B. Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku, Ivo Abraham
Publikováno v:
Journal of medical economics. 24(sup1)
To demonstrate how medical purchasing power parities (mPPP) may harmonize economic evaluations from different jurisdictions and enable comparisons across jurisdictions.We describe the use of mPPPs and illustrate this with an example of economic evalu
Autor:
Briana M Choi, Rachel B Abraham, Osama Aqel, Uche S Agu, Kristen C. Gregory, Mavis Obeng-Kusi, Matthias Calamia, Hala Halawah, Deniz Tugay, Ahmad Alamer, Ali McBride, Ivo Abraham
Publikováno v:
Journal of Clinical Oncology. 40:e20502-e20502
e20502 Background: Patients with stage 1B non-small cell lung cancer (NSCLC) who receive surgical resection are at continued risk of disease recurrence and death after the surgery. Osimertinib, a tyrosine kinase inhibitor indicated for epidermal grow
Autor:
Briana M Choi, Osama Aqel, Rachel B Abraham, Mavis Obeng-Kusi, Matthias Calamia, Hala Halawah, Ahmad Alamer, Ali McBride, Ivo Abraham, Deniz Tugay
Publikováno v:
Journal of Clinical Oncology. 40:e20506-e20506
e20506 Background: Following surgical resection, patients with NSCLC require monitoring due to the risk of recurrence. Studies have demonstrated the clinical benefit of osimertinib, a tyrosine kinase inhibitor, as adjunctive therapy in surgically res
Autor:
Mavis Obeng-Kusi, Briana M Choi, Rachel B Abraham, Osama Aqel, Matthias Calamia, Hala Halawah, Deniz Tugay, Ahmad Alamer, Ali McBride, Ivo Abraham
Publikováno v:
Journal of Clinical Oncology. 40:e20505-e20505
e20505 Background: Patients with surgically resected EGFR+ NSCLC remain at risk of recurrence after surgery. Osimertinib, a tyrosine kinase inhibitor, had been assessed clinically as adjunctive therapy in surgically resected EGFR+ NSCLC including sta
Autor:
Ivo Abraham, Matthias Calamia, Nimer S. Alkhatib, Briana Choi, AlMothana Manasrah, Odai Alkhdour, Dexter Gulick, Hala Halawah, Ali McBride
Publikováno v:
Journal of Clinical Oncology. 39:e21104-e21104
e21104 Background: Crizotinib, alectinib, ceritinib, and brigatinib are approved as second line treatment for ALK+ NSCLC. Crizotinib was the first ALK inhibitor for first line therapy approved by Food and Drug Administration (2011) then ceritinib (20
Publikováno v:
Journal of Clinical Oncology. 39:e19535-e19535
e19535 Background: PBR and TafaL are two recently regulatory approved regimens that offer treatment options for R/R DLBCL patients who are ASCT ineligible or choose not to undergo ASCT. PBR is administered over 6 cycles, whereas TafaL is sustained un
Publikováno v:
Journal of Clinical Oncology. 39:e20010-e20010
e20010 Background: Isatuximab and daratumumab target the CD38 transmembrane glycoprotein on MM cells. IKd and DKd regimens have shown reductions of HR=0.53 (95%CI 0.32-0.89) and HR=0.63 (95%CI 0.46-0.85) resp. in progression or death risk compared to